{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T12:35:02Z","timestamp":1763382902215,"version":"3.45.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG078759"],"award-info":[{"award-number":["R01AG078759"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s00198-025-07672-1","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T12:13:18Z","timestamp":1756987998000},"page":"2197-2206","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The relationship between osteoporosis treatment history and receipt of a second zoledronic acid dose"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4100-8650","authenticated-orcid":false,"given":"Natalia","family":"Konstantelos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela M.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea M.","family":"Burden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Grootendorst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne M.","family":"Cadarette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"issue":"8","key":"7672_CR1","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1185\/030079904125004475","volume":"20","author":"G Rodan","year":"2004","unstructured":"Rodan G et al (2004) Bone safety of long-term bisphosphonate treatment. Curr Med Res Opin 20(8):1291\u20131300","journal-title":"Curr Med Res Opin"},{"key":"7672_CR2","unstructured":"Ministry of Health (2025) Get coverage for prescription drugs. Available from:  https:\/\/www.ontario.ca\/page\/get-coverage-prescription-drugs. Accessed 13 Jan 2025"},{"issue":"17","key":"7672_CR3","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1503\/cmaj.100771","volume":"182","author":"A Papaioannou","year":"2010","unstructured":"Papaioannou A et al (2010) 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 182(17):1864\u20131873","journal-title":"CMAJ"},{"key":"7672_CR4","unstructured":"(2018) Drug programs policy and strategy branch ontario public drug programs ministry of health and long-term care. Ontario drug benefit formulary\/comparative drug index edition 43: summary of changes\u00a0"},{"issue":"39","key":"7672_CR5","doi-asserted-by":"publisher","first-page":"E1333","DOI":"10.1503\/cmaj.221647","volume":"195","author":"SN Morin","year":"2023","unstructured":"Morin SN et al (2023) Clinical practice guideline for management of osteoporosis and fracture prevention in Canada: 2023 update. CMAJ 195(39):E1333\u2013e1348","journal-title":"CMAJ"},{"issue":"3","key":"7672_CR6","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/jbmr.3318","volume":"33","author":"MA Amiche","year":"2018","unstructured":"Amiche MA et al (2018) Effectiveness of oral bisphosphonates in reducing fracture risk among oral glucocorticoid users: three matched cohort analyses. J Bone Miner Res 33(3):419\u2013429","journal-title":"J Bone Miner Res"},{"issue":"5","key":"7672_CR7","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/MLR.0000000000001294","volume":"58","author":"JR Curtis","year":"2020","unstructured":"Curtis JR et al (2020) Duration of bisphosphonate drug holidays and associated fracture risk. Med Care 58(5):419\u2013426","journal-title":"Med Care"},{"issue":"1","key":"7672_CR8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.7326\/M19-0533","volume":"171","author":"HA Fink","year":"2019","unstructured":"Fink HA et al (2019) Long-term drug therapy and drug discontinuations and holidays for osteoporosis fracture prevention: a systematic review. Ann Intern Med 171(1):37\u201350","journal-title":"Ann Intern Med"},{"issue":"2","key":"7672_CR9","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3803\/EnM.2021.1369","volume":"37","author":"WL Tay","year":"2022","unstructured":"Tay WL, Tay D (2022) Discontinuing denosumab: can it be done safely? A review of the literature. Endocrinol Metab (Seoul) 37(2):183\u2013194","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"1","key":"7672_CR10","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3390\/jcm10010152","volume":"10","author":"AD Anastasilakis","year":"2021","unstructured":"Anastasilakis AD et al (2021) Denosumab discontinuation and the rebound phenomenon: a narrative review. J Clin Med 10(1):152","journal-title":"J Clin Med"},{"issue":"7","key":"7672_CR11","doi-asserted-by":"publisher","first-page":"516","DOI":"10.7326\/M20-0882","volume":"173","author":"H Lyu","year":"2020","unstructured":"Lyu H et al (2020) Delayed denosumab injections and fracture risk among patients with osteoporosis\u202f: a population-based cohort study. Ann Intern Med 173(7):516\u2013526","journal-title":"Ann Intern Med"},{"key":"7672_CR12","doi-asserted-by":"publisher","first-page":"115150","DOI":"10.1016\/j.bone.2019.115150","volume":"130","author":"L Tripto-Shkolnik","year":"2020","unstructured":"Tripto-Shkolnik L et al (2020) Fracture incidence after denosumab discontinuation: real-world data from a large healthcare provider. Bone 130:115150","journal-title":"Bone"},{"issue":"6","key":"7672_CR13","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1002\/jbmr.3110","volume":"32","author":"AD Anastasilakis","year":"2017","unstructured":"Anastasilakis AD et al (2017) Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res 32(6):1291\u20131296","journal-title":"J Bone Miner Res"},{"issue":"6","key":"7672_CR14","doi-asserted-by":"publisher","first-page":"ziaf061","DOI":"10.1093\/jbmrpl\/ziaf061","volume":"9","author":"KN Hayes","year":"2025","unstructured":"Hayes KN et al (2025) Real-world differences in denosumab persistence, reinitiation, and switching among cohorts of older adults in Canada and the United States. JBMR Plus 9(6):ziaf061","journal-title":"JBMR Plus"},{"key":"7672_CR15","doi-asserted-by":"publisher","unstructured":"Tsourdi E, Zillikens MC, Meier C, Body JJ, Gonzalez Rodriguez E, Anastasilakis AD, Abrahamsen B, McCloskey E, Hofbauer LC, Gua\u00f1abens N, Obermayer-Pietsch B, Ralston SH, Eastell R, Pepe J, Palermo A, Langdahl B (2020) Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab. dgaa756. https:\/\/doi.org\/10.1210\/clinem\/dgaa756","DOI":"10.1210\/clinem\/dgaa756"},{"issue":"10","key":"7672_CR16","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1007\/s00198-021-05900-y","volume":"33","author":"MS LeBoff","year":"2022","unstructured":"LeBoff MS et al (2022) The clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int 33(10):2049\u20132102","journal-title":"Osteoporos Int"},{"issue":"3","key":"7672_CR17","doi-asserted-by":"publisher","first-page":"232","DOI":"10.4212\/cjhp.v68i3.1457","volume":"68","author":"SM Cadarette","year":"2015","unstructured":"Cadarette SM, Wong L (2015) An introduction to health care administrative data. Can J Hosp Pharm 68(3):232\u2013237","journal-title":"Can J Hosp Pharm"},{"issue":"2","key":"7672_CR18","first-page":"1135","volume":"4","author":"M Schull","year":"2020","unstructured":"Schull M et al (2020) ICES: data, discovery, better health. Int J Popul Data Sci 4(2):1135","journal-title":"Int J Popul Data Sci"},{"issue":"7","key":"7672_CR19","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1007\/s00198-020-05794-2","volume":"32","author":"KN Hayes","year":"2021","unstructured":"Hayes KN et al (2021) Over half of seniors who start oral bisphosphonate therapy are exposed for 3 or more years: novel rolling window approach and patterns of use. Osteoporos Int 32(7):1413\u20131420","journal-title":"Osteoporos Int"},{"issue":"11","key":"7672_CR20","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1007\/s00198-009-1134-4","volume":"21","author":"I Imaz","year":"2010","unstructured":"Imaz I et al (2010) Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int 21(11):1943\u20131951","journal-title":"Osteoporos Int"},{"key":"7672_CR21","unstructured":"(2025) Waterloo Regional Health Network. Patient eligibility for OHIP funded bone density examinations. Available from:  https:\/\/www.grhosp.on.ca\/care\/services-departments\/medical-imaging\/medical-imaging\/patient-eligibility-for-ohip-funded-bone-density-examinations. Accessed 13 Jan 2025"},{"issue":"5","key":"7672_CR22","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1007\/s00198-014-3023-8","volume":"26","author":"AM Burden","year":"2015","unstructured":"Burden AM et al (2015) Uptake and characteristics of zoledronic acid and denosumab patients and physicians in Ontario, Canada: impact of drug formulary access. Osteoporos Int 26(5):1525\u20131533","journal-title":"Osteoporos Int"},{"issue":"5","key":"7672_CR23","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/jc.2019-00221","volume":"104","author":"R Eastell","year":"2019","unstructured":"Eastell R et al (2019) Pharmacological management of osteoporosis in postmenopausal women: an endocrine society* clinical practice guideline. J Clin Endocrinol Metab 104(5):1595\u20131622","journal-title":"J Clin Endocrinol Metab"},{"key":"7672_CR24","unstructured":"(2023) Dr.Reddy\u2019s Laboratories Ltd., Patient care program - it\u2019s not just about medicine.\u00a0https:\/\/www.drreddys.ca\/patient-care-program. Accessed 13 Jan 2025\u00a0"},{"key":"7672_CR25","unstructured":"(2012) Drug Programs Policy and Strategy Branch Ontario Public Drug Programs Ministry of Health and Long-Term Care., Ontario drug benefit formulary\/comparative drug index no. 41 effective February 29, 2012 Summary of Changes. Accessed 13 Jan 2025"},{"key":"7672_CR26","unstructured":"King\u2019s Printer for Ontario (2024) Limited use note(s): zoledronic acid 5mg\/100mL Inj Sol-100mL Pk (preservative-free). Accessed 13 Jan 2025"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07672-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-025-07672-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07672-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T12:32:22Z","timestamp":1763382742000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-025-07672-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["7672"],"URL":"https:\/\/doi.org\/10.1007\/s00198-025-07672-1","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"type":"print","value":"0937-941X"},{"type":"electronic","value":"1433-2965"}],"subject":[],"published":{"date-parts":[[2025,9,4]]},"assertion":[{"value":"17 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Acknowledgement has been updated.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}